On Sept. 3, 2025, C2N Diagnostics (C2N), a specialty diagnostics company announce that its early achievements while based in St. Louis are allowing it to triple the size of its operations in its hometown. C2N, a leader in advanced brain health diagnostics, will relocate its headquarters and expand its federally regulated CAP accredited-CLIA certified lab operation to 4140 Forest Park Ave. at Catalyst, Powered by WashU, in the Cortex Innovation District in Midtown.

Washington University is redeveloping the former Goodwill Industries International site. The new lab will leverage the latest advancements in bioautomation and high-resolution, high-throughput proteomic testing. Altogether, C2N will occupy 82,451 new square feet at Catalyst, filling the first three floors. C2N expects to begin the move in late 2026.

In addition to the new headquarters, C2N will maintain its existing ISO 13485:2016 compliant lab facility and turn it into a center dedicated to providing cutting edge multi-omic solutions and advanced analytical platforms to drive innovation across its biopharmaceutical research services and medtech business units, and international collaborative research initiatives.

C2N is best known for commercializing the first clinical blood test for Alzheimer’s disease and more recently for its highly accurate PrecivityAD2™ blood test, which helps health care professionals in the detection of amyloid plaques in the brain, a pathological hallmark of Alzheimer’s disease, and inform medical management and treatment decisions.

With over 50,000 Precivity™ analytes reported in peer-reviewed publications and over 150 academic, clinical, and research collaborations globally using Precivity biomarkers, C2N has significantly impacted Alzheimer’s research. C2N is now expanding the biomarker pipeline by developing advanced assays targeting tau pathology, Parkinson’s disease research, and developing technologies to decentralize mass spectrometry testing.